September 28, 2024
With so many shifts and shakeups in and around the industry, there are many “new” companies have been coming on the scene lately within our space that realistically are made up of highly-experienced people migrating over from other organizations. As a relatively new company, Envol Biomedical is just such an organization, and therefore has only attended the American College of Toxicology’s (ACT) annual meeting for a couple of years now, but the overwhelming majority of the individuals who now work at Envol are no strangers to the event, and have been attending for many years – decades, even.
The Importance of ACT Within the Toxicology Space
ACT as a leading toxicology meeting for the drug development space, and we find there is a lot of value in attending. I have personally been going for probably 5 or 6 years, but many on my team at Envol have been attending their entire careers. Historically, there have been other meetings with toxicology at its core, but ACT has really been shown a lot of leadership over the last number of years. Whereas other meetings are getting more and more diluted and wider in their focus in serving the needs of our community, ACT has remained devoted to the areas of of advancing human health as it relates to toxicology and the development of new drugs. This is, in my opinion, one of the reasons why it has grown quite a bit, while other organizational meetings are seeing a decrease in attendance.
ACT is especially important for Envol this year because of the story we have to tell about our growth, our expansion, and our renewed focus on our quality of training. ACT really caters to people who are conducting studies related to toxicology, meaning that most of the attendees are individuals involved with organizations that have recently identified their lead candidate, and they know they want to take that candidate to the clinic. This is an area Envol been excited to show customers in terms of our ability to work with clients all the way into the clinic. For us, letting people know what our progress has been over the last year or so and how we aim to be a strong partner for them, and ultimately how we are going to help reduce risk.
This is going to be a big year for Envol at ACT!
We have so many things to share at ACT this year, beginning with the simple fact that we’re bigger now – we have grown. Envol has also taken major strides on developing our GLP infrastructure, making us a more ideal partner for those transitioning to the toxicology phase of their development. It is sometimes difficult to set yourself apart in such a competitive market, but for Envol the stories we have to share will actually make it pretty clear to our prospective customers that we are the right choice right now. Our planning and forecasting has placed us in a position wherein we can start projects faster, and finish them sooner. Additionally, our flexibility and our access to resources that are pretty unparalleled, not the least of which is having the largest selection of nonhuman primate in North America.
We want you to stop by and see us in Austin!
If you are someone who is developing a biologic or antibody and you are looking to have a real partner in your development process – and not just in the cliche way everyone offers – but where you can genuinely get to know the team, visit the site, participate in the research, and feel like we are a part of your study team, then Envol is the right choice for you.
With Envol, you will meet an extremely competent and high qualified set of professionals who are focused on identifying the things your study requires in terms of data turnaround, data integrity, and meeting deadlines. And as a boutique facility, we are a relatively smaller lab that will cater to your needs more so than a bigger laboratory.
Come visit us at booth 217, we look forward to seeing everyone in Austin and sharing our story with you there!
